Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amphastar is a biopharmaceutical company focused on complex generic and proprietary injectable, inhalation, and intranasal products and insulin API products, and its filings offer detailed insight into how this business is structured and governed.
Investors reviewing AMPH filings will find current reports on Form 8-K that describe material events such as license agreements, contract research agreements, manufacturing and distribution amendments, and related-party transactions with entities affiliated with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. These 8-Ks outline key terms for agreements covering proprietary peptides, AMP-110, recombinant peptide research cell banks for AMP-107, and regional distribution of BAQSIMI®.
Amphastar also files earnings-related 8-Ks that furnish press releases summarizing quarterly financial results, including net revenues, net income, and non-GAAP measures such as adjusted net income and adjusted diluted EPS. These disclosures explain how the company evaluates its operating performance and reconcile non-GAAP metrics to GAAP figures.
Through Stock Titan, users can monitor real-time updates from EDGAR as new Amphastar filings appear, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available. AI-powered summaries help explain the significance of complex agreements, highlight changes in licensing and manufacturing arrangements, and surface important details about pipeline assets, manufacturing footprint, distribution partnerships, and governance matters. The filings page also makes it easier to track board and management changes, share repurchase authorizations, and other corporate actions that Amphastar reports to the SEC.
Amphastar Pharmaceuticals director and CFO William J. Peters reported a routine tax-related share disposition. On March 6, 2026, 2,146 shares of common stock were withheld at $19.34 per share to satisfy his tax liability from vesting restricted stock units. After this withholding, he directly owned 121,640 shares of Amphastar common stock.
Amphastar Pharmaceuticals senior executive Rong Zhou reported a routine tax-related share disposition. On March 6, 2026, 1,357 shares of common stock were withheld at $19.34 per share to cover taxes from vesting restricted stock units. After this withholding, Zhou directly held 135,562 shares, with additional indirect holdings of 99,668 shares through the Zhou Family Trust and 5,000 shares held by the spouse, as noted in the footnotes. This filing reflects compensation- and tax-driven activity rather than an open-market trade.
Amphastar Pharmaceuticals EVP Liawatidewi Yakob reported a routine tax-related share disposition. On March 6, 2026, 1,144 shares of common stock were withheld at $19.34 per share to cover taxes on vesting restricted stock units, not as an open-market sale.
After this withholding, Yakob directly holds 89,345 shares of Amphastar common stock and indirectly holds 2,459 shares through the Yakob and Sunmoon Trust dated July 25, 2013, where she serves as trustee.
Amphastar Pharmaceuticals director and CEO Jack Y. Zhang reported routine tax-related share withholdings tied to restricted stock unit vesting. On March 6, 2026, a total of 10,850 shares of common stock were withheld to satisfy tax liabilities, rather than sold on the open market.
After these withholdings, Zhang holds 2,834,117 shares directly. Additional indirect holdings include 1,179,966 shares held of record by his spouse, Mary Z. Luo, and 6,827,679 shares held through Applied Physics and Chemistry Laboratories, Inc. and a related family trust.
Amphastar Pharmaceuticals insiders reported tax-related share withholdings tied to equity compensation, not open-market sales. CEO and Chief Scientific Officer Jack Y. Zhang had 5,769 shares of common stock withheld at $19.96 per share to satisfy tax liabilities from vesting restricted stock units, leaving 2,841,890 shares held directly.
Additional tax-withholding dispositions of 2,432 common shares at $19.96 per share were reported as indirectly owned, with 1,183,043 indirect shares remaining. Footnotes state that some securities are held of record by Mary Z. Luo and that 6,827,679 shares are held of record by Applied Physics and Chemistry Laboratories, Inc., which is owned by the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust.
Amphastar Pharmaceuticals senior executive Rong Zhou reported a small share disposition related to taxes, not an open-market sale. On the RSU vesting date, 1,124 shares of common stock were withheld at $19.96 per share to cover Zhou’s tax liability, leaving 136,919 shares held directly. In addition, 99,668 shares are held indirectly through the Zhou Family Trust, where Zhou serves as trustee, and 5,000 shares are held by Zhou’s spouse.
Amphastar Pharmaceuticals director and EVP Liawatidewi Yakob reported a tax-related share disposition. On March 4, 2026, 965 shares of common stock were withheld at $19.96 per share to satisfy her tax liability upon vesting of restricted stock units.
After this tax-withholding disposition, she directly held 90,489 common shares. She also indirectly held 2,459 shares through the Yakob and Sunmoon Trust dated July 25, 2013, which includes 545 shares acquired on May 31, 2025 under Amphastar’s 2014 Employee Stock Purchase Plan.
Amphastar Pharmaceuticals CFO William J. Peters had 1,744 shares of common stock withheld at $19.96 per share to cover taxes from vesting restricted stock units. After this tax-withholding disposition, he directly owns 123,786 shares, which include 545 shares acquired under the company’s 2014 Employee Stock Purchase Plan.
Amphastar Pharmaceuticals, Inc. reported new executive employment agreements for Jacob Liawatidewi and Rong Zhou effective March 3, 2026. Each agreement has a one-year term that automatically renews unless either party gives 90 days’ notice and can be terminated at any time with or without cause or good reason.
Liawatidewi will receive an annual base salary of $525,800 with a target cash bonus equal to 55% of base salary, while Zhou will receive $590,000 with a 53% target bonus. Both are eligible for equity incentives and standard company benefit plans.
On a qualifying termination, they may receive severance benefits subject to signing a release, with additional severance if it occurs within one year after a change in control. Upon any change in control during employment, 100% of their unvested equity awards will vest. Payments are also structured to address potential Section 280G excise taxes.
Amphastar Pharmaceuticals outlined two agreements with Chinese affiliates that it does not view as material to its financial results. Its subsidiary Amphastar Nanjing Pharmaceuticals signed a five-year supply agreement with Nanjing Letop Biotechnology, under which Letop will provide chemical intermediates. Amphastar can choose order volumes at its discretion and is not required to buy any minimum quantity. Payments will be made in Chinese yuan, and Amphastar retains ownership of shared confidential information.
Separately, Amphastar amended its contract research arrangement with Nanjing Hanxin Pharmaceutical Technology. The company will use Hanxin’s research cell banks to develop Master Cell Banks for product candidate AMP-105 instead of AMP-107. This change increases the total contract cost by about $0.6 million. Both Letop and Hanxin are majority-owned by family members of senior executives, and Amphastar’s Audit Committee reviewed and approved these related party transactions.